{"title":"膀胱癌的诊断","authors":"P. Pathak","doi":"10.35248/2329-6917.21.9.E119","DOIUrl":null,"url":null,"abstract":"Transitional-cell carcinoma, which constitutes the vast majority of bladder cancers in the United States, may develop as carcinoma in situ or as invasive carcinoma. This article focuses on transitional-cell carcinoma with a review of the major aspects of the disease, including the epidemiology, diagnosis and staging, and management. Therapeutic options are explored, including surgery, radiotherapy, chemotherapy, and combined modality therapy.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"9 1","pages":"1-1"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Diagnosis of Bladder Cancer\",\"authors\":\"P. Pathak\",\"doi\":\"10.35248/2329-6917.21.9.E119\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Transitional-cell carcinoma, which constitutes the vast majority of bladder cancers in the United States, may develop as carcinoma in situ or as invasive carcinoma. This article focuses on transitional-cell carcinoma with a review of the major aspects of the disease, including the epidemiology, diagnosis and staging, and management. Therapeutic options are explored, including surgery, radiotherapy, chemotherapy, and combined modality therapy.\",\"PeriodicalId\":90223,\"journal\":{\"name\":\"Journal of leukemia (Los Angeles, Calif.)\",\"volume\":\"9 1\",\"pages\":\"1-1\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of leukemia (Los Angeles, Calif.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/2329-6917.21.9.E119\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of leukemia (Los Angeles, Calif.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2329-6917.21.9.E119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Transitional-cell carcinoma, which constitutes the vast majority of bladder cancers in the United States, may develop as carcinoma in situ or as invasive carcinoma. This article focuses on transitional-cell carcinoma with a review of the major aspects of the disease, including the epidemiology, diagnosis and staging, and management. Therapeutic options are explored, including surgery, radiotherapy, chemotherapy, and combined modality therapy.